Aditya Uppuluri1, Marco A Zarbin1, Neelakshi Bhagat2. 1. Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Doctors Office Center, 90 Bergen Street, Suite 6100, Newark, NJ, 07103, USA. 2. Department of Ophthalmology and Visual Science, Rutgers New Jersey Medical School, Doctors Office Center, 90 Bergen Street, Suite 6100, Newark, NJ, 07103, USA. bhagatne@njms.rutgers.edu.
Abstract
PURPOSE: To identify risk factors for endogenous endophthalmitis (EE) in hospitalized adults, under 65 years of age, with a history of intravenous opioid use and non-ocular infection. METHODS: The National Inpatient Sample Database was used to identify cases of EE with a recent history of intravenous opioid use disorder with associated non-ocular infection. Systemic and ocular comorbidities were identified using codes from the International Classification of Diseases, Ninth Revision (ICD-9). Descriptive and regression analyses were performed to evaluate the risk factors for EE using IBM SPSS 23. RESULTS: Of the 605,859 inpatients, 21-65 years age, who had a history of recent opioid-IVDU and an associated IVDU-associated systemic infection, 363 (0.1%) had EE. Systemic comorbidities such as diabetes mellitus, mitral valve disease, aortic valve disease, history of cardiac valve transplantation, chronic kidney disease/renal failure, cirrhosis, active or previous radiation therapy, and history of solid organ transplantation were significantly more prevalent in patients with EE. A significantly increased risk of EE in intravenous opioid users was noted if they were of male gender (OR = 1.84), Asian/Pacific Islander ethnicity (OR = 4.41), had history of cirrhosis (OR = 2.33), active or history of radiation therapy (OR = 14.74), history of solid organ transplantation (OR = 5.91), candidemia (OR = 15.22), and infectious endocarditis (OR = 4.83). Conversely, concurrent alcohol use disorder (OR = 0.35) decreased the risk of EE. CONCLUSION: Various demographic variables and systemic comorbidities increased the risk of developing EE in inpatients with a history of intravenous opioid use with associated non-ocular infection.
PURPOSE: To identify risk factors for endogenous endophthalmitis (EE) in hospitalized adults, under 65 years of age, with a history of intravenous opioid use and non-ocular infection. METHODS: The National Inpatient Sample Database was used to identify cases of EE with a recent history of intravenous opioid use disorder with associated non-ocular infection. Systemic and ocular comorbidities were identified using codes from the International Classification of Diseases, Ninth Revision (ICD-9). Descriptive and regression analyses were performed to evaluate the risk factors for EE using IBM SPSS 23. RESULTS: Of the 605,859 inpatients, 21-65 years age, who had a history of recent opioid-IVDU and an associated IVDU-associated systemic infection, 363 (0.1%) had EE. Systemic comorbidities such as diabetes mellitus, mitral valve disease, aortic valve disease, history of cardiac valve transplantation, chronic kidney disease/renal failure, cirrhosis, active or previous radiation therapy, and history of solid organ transplantation were significantly more prevalent in patients with EE. A significantly increased risk of EE in intravenous opioid users was noted if they were of male gender (OR = 1.84), Asian/Pacific Islander ethnicity (OR = 4.41), had history of cirrhosis (OR = 2.33), active or history of radiation therapy (OR = 14.74), history of solid organ transplantation (OR = 5.91), candidemia (OR = 15.22), and infectious endocarditis (OR = 4.83). Conversely, concurrent alcohol use disorder (OR = 0.35) decreased the risk of EE. CONCLUSION: Various demographic variables and systemic comorbidities increased the risk of developing EE in inpatients with a history of intravenous opioid use with associated non-ocular infection.
Entities:
Keywords:
Endogenous endophthalmitis; Endophthalmitis; Intraocular infection; Intravenous drug use; Sepsis
Authors: Michael S Spencer; Juan Chen; Gilbert C Gee; Cathryn G Fabian; David T Takeuchi Journal: Am J Public Health Date: 2010-03-18 Impact factor: 9.308
Authors: S B Hashemi; M Shishegar; S Nikeghbalian; H Salahi; A Bahador; K Kazemi; M Dehghani; F Kakaei; S Gholami; P Janghorban; S A Malek-Hosseini Journal: Transplant Proc Date: 2009-09 Impact factor: 1.066
Authors: J Bisbe; J M Miro; X Latorre; A Moreno; J Mallolas; J M Gatell; J P de la Bellacasa; E Soriano Journal: Clin Infect Dis Date: 1992-12 Impact factor: 9.079
Authors: Louisa Degenhardt; Amy Peacock; Samantha Colledge; Janni Leung; Jason Grebely; Peter Vickerman; Jack Stone; Evan B Cunningham; Adam Trickey; Kostyantyn Dumchev; Michael Lynskey; Paul Griffiths; Richard P Mattick; Matthew Hickman; Sarah Larney Journal: Lancet Glob Health Date: 2017-10-23 Impact factor: 26.763